NEW YORK - Psyence Biomedical Ltd. (NASDAQ:PBM), a biopharmaceutical company specializing in psilocybin-based treatments, announced today that it will not proceed with the acquisition of Clairvoyant Therapeutics, Inc. The decision comes after the completion of due diligence activities in line with the conditional binding term sheet dated September 9, 2024. Despite this development, Psyence Biomed continues to progress with its Phase IIb clinical trial, investigating the use of nature-derived psilocybin in conjunction with psychotherapy for Adjustment Disorder in palliative care. The trial is expected to commence patient randomization this quarter, with topline data anticipated in the second half of 2025.
In addition to the ongoing trial, Psyence Biomed is advancing its study of psilocybin for Substance Use Disorders, focusing first on Alcohol Use Disorder. The company has recently entered into an exclusive IP licensing agreement with PsyLabs, a producer of psychedelic active pharmaceutical ingredients. Psyence Biomed also plans to acquire an 11.13% stake in PsyLabs, with due diligence currently underway and an update on this transaction expected soon.
Dr. Neil Maresky, CEO of Psyence Biomed, expressed that while the acquisition of Clairvoyant did not materialize, the company remains committed to leading the development of psilocybin-based therapeutics for mental health and addiction disorders. He conveyed optimism about the company's ongoing development programs and the pursuit of strategic opportunities aligned with their clinical strategy.
Psyence Biomed is recognized as one of the first biotechnology firms focusing on non-synthetic, nature-derived psychedelic medicines to list on Nasdaq. The company's mission is to address unmet needs in mental health within the context of Palliative Care through evidence-based research and development.
The company's forward-looking statements outline its intentions regarding the proposed acquisition of PsyLabs and its clinical strategies but are subject to various risks and uncertainties, including regulatory approvals and the efficacy and safety of psilocybin as a treatment option. These statements are based on assumptions and reflect the company's current expectations, which may change over time.
This article is based on a press release statement from Psyence Biomedical Ltd. and contains no endorsement of the company's claims. The information provided is for general news purposes and should not be considered as medical advice or a recommendation of the company's products.
In other recent news, Psyence Biomedical has been making strategic moves to bolster its position in the development of treatments for mental health conditions using psychedelic substances. The company has acquired an 11.13% stake in PsyLabs, a producer of psychedelic active pharmaceutical ingredients, for $1.1 million. The acquisition is expected to support Psyence Biomed's long-term success by ensuring a consistent supply of high-quality psilocybin. In parallel, Psyence Biomedical has also announced a conditional agreement to acquire Canada-based clinical-stage company Clairvoyant Therapeutics Inc., with the aim of expanding its pipeline with a synthetic psilocybin candidate for treating Alcohol Use Disorder (AUD).
Simultaneously, Psyence Biomedical has entered into an exclusive licensing agreement with PsyLabs to secure a supply of EU GMP nature-derived psilocybin for future clinical trials. However, the company has been notified by Nasdaq of its potential delisting due to failure to meet minimum market value requirements. Psyence Biomedical plans to request a hearing before a Nasdaq Hearings Panel to delay any suspension or delisting actions. These recent developments are part of Psyence Biomed's focus on evidence-based approaches in developing treatments for mental health disorders.
InvestingPro Insights
Psyence Biomedical Ltd.'s financial metrics and market performance provide additional context to the company's recent developments. As of the latest data from InvestingPro, PBM's market capitalization stands at a modest $1.72 million, reflecting its early-stage status in the biopharmaceutical industry.
The company's financial health appears challenging, with an adjusted operating income of -$2.75 million for the last twelve months as of Q4 2024. This negative figure aligns with the company's focus on research and development in the emerging field of psilocybin-based treatments, where significant investments are typically required before potential commercialization.
PBM's stock performance has been notably volatile, with a one-year price total return of -99.08% and a year-to-date return of -98.89%. These figures underscore the high-risk nature of investing in early-stage biopharmaceutical companies, especially those working with novel treatments like psychedelics.
An InvestingPro Tip highlights that PBM's price is near its 52-week low, currently at just 0.69% of its 52-week high. This could be of interest to investors looking for potentially undervalued opportunities in the biotech sector, though it also reflects the market's current skepticism about the company's prospects.
Another InvestingPro Tip notes that analysts do not expect PBM to be profitable this year. This aligns with the company's current focus on clinical trials and research rather than immediate revenue generation.
For readers interested in a deeper analysis, InvestingPro offers 12 additional tips for Psyence Biomedical Ltd., providing a more comprehensive view of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.